

22-25 JANUARY 2018 | HYATT REGENCY, MIAMI



Phacilitate

IMMUNO-ONCOLOGY FRONTIERS WORLD

FROM SCIENCE TO STRATEGY

Also part of the Phacilitate Leaders Forum



Phacilitate

CELL & GENE
THERAPY WORLD

SUPER
EARLY BIRD
ENDS
OCTOBER 20!



300+
Attendees



150
Organisations



70+
Speakers



20+
Countries

MEET THE SPEAKERS!



Dr Mene Pangalos
Executive Vice President,
Innovative Medicine & Early
Development Biotech Unit
AstraZeneca



Dr Tim Anderson
Senior Analyst
Sanford C. Bernstein



Dr Pascal Touchon
SVP Global Head Strategy
BD&L
Novartis



Dr Steven Peskin
Executive director of Population Health
**Horizon Blue Cross Blue Shield of
New Jersey**



Jeff Evelhoch
VP, Head of Translational
Biomarkers
Merck Research Laboratories



Robert Weisskoff, Ph.D.
Partner
F-Prime Capital Partners



Ferran Prat
Senior Vice President, Research
Administration & Industry Relations
MD Anderson Cancer Center



Dr. James J. Mulé
Associate Center Director,
Translational Research, Director
of Cell-Based Immunotherapies
Moffitt Cancer Center



Dr Bent Jakobsen
CSO
Immunocore

Platinum sponsor

ThermoFisher
SCIENTIFIC

Find out more at www.iofrontiersworld.com

THE WORLD'S MOST SENIOR AND INFLUENTIAL PARTNERING MEETING FOR IMMUNO-ONCOLOGY

"THEIR CONFERENCES AND PUBLICATIONS RELATED TO IO ARE THE MOST TARGETED AND CONCENTRATED IN THE INDUSTRY, THEY HAVE DONE A TERRIFIC JOB OF PULLING TOGETHER LEADERS IN THE FIELD AND IN REACHING THE IO COMMUNITY"

Dr Llew Keltner, CEO, Epistat



PHACILITATE LEADERS FORUM MIAMI

The biggest and most influential meeting for Advanced Therapies in the world. Meet more decision makers in 4 days than you can in 4 months, from themed cocktail receptions on the banks of the Miami Canals to the already-legendary Phacilitate Miami Yacht Party, we set a brand new standard for informal networking and partnering.



2 EVENTS FOR THE PRICE OF 1

The only event to bring together the full ecosystem and KOLs from across cell, gene and immunotherapy. Phacilitate will bring together Industry, scientific and business leaders to forge the partnerships speeding up innovation in immuno-oncology



BE PART OF THE LARGEST SHOWCASE OF GROUND-BREAKING SOLUTIONS!

Phacilitate Leaders Forum Miami delivers the largest, most interactive exhibition featuring the most innovative solution providers with the tools that you need

“ IT WAS A GREAT OPPORTUNITY TO SHARE CURRENT DATA AND THINKING ABOUT THE DEVELOPMENT OF THERAPEUTICS DIRECTED AT MODULATING THE IMMUNE RESPONSE TO CANCER. ”

LANCE LEOPOLD, VICE PRESIDENT, HEAD OF ONCOLOGY DEVELOPMENT, INCYTE CORPORATION



CONNECTING EMERGING SCIENCE WITH BUSINESS AND TECHNOLOGY LEADERS

Meet more decision makers in 4 days than you can in 4 months! With a complete dedication to showcasing the most exciting emerging science, I-O Frontiers will put the spotlight on the next generation of biotech innovators.



NEW: JOIN US AT OUR UNIQUE IMMUNO-ONCOLOGY HUB

Connect with the future! Gain expert insights from solution providers and technology disruptors who are key to the progress of pre clinical and clinical development in I-O. Don't miss groundbreaking demonstrations that will educate and inform your future business decisions.

FUN, EFFECTIVE NETWORKING

Setting a brand new standard for networking. From themed cocktail receptions on the banks of the Miami Canals, our I-O Partnering Lunch or our already-legendary Phacilitate Miami Yacht Party, Phacilitate Leaders Forum 2018 will support your partnering activities like never before.

GENUINE MUST ATTEND



Independent research from AMR International scored the event 4.5/5 - join 'the world's leading partnering event'

"Rated Excellent"

PRICELESS STRATEGIC & TACTICAL BUSINESS INSIGHT

Stay ahead of the game. Understand successful business and commercialization models. Identify future technologies and trends. Capitalize on opportunities!

AN EXPERT PANEL OF SPEAKERS

Dr Mene Pangalos

Executive Vice President, Innovative Medicine & Early Development Biotech Unit
AstraZeneca

Dr Tim Anderson

Senior Analyst
Sanford C. Bernstein

Dr Pascal Touchon

SVP Global Head Strategy BD&L
Novartis

Dr Roy Baynes

SVP & Head Global Clinical Development, Chief Medical Officer
Merck Research Laboratories

Dr Alise Reicin

SVP, Head of Global Clinical Development
EMD Serono

Dr Tatjana Kolevska

Oncologist
Kaiser Permanente

Steven Peskin, MD;

Executive Medical Director, Population Health,
Horizon Blue Cross Blue Shield of New Jersey

Dr Stanley Frankel

Corporate Vice President, Head Immuno-Oncology R&D
Celgene

Jeff Evelhoch

VP, Head of Translational Biomarkers
Merck Research Laboratories

Aiman Shalabi

Chief Medical Officer, Venture Fund, Clinical Accelerator
Cancer Research Institute

Robert Weisskoff Ph.D. -

Partner
F-Prime Capital Partners

Brad Loncar

CEO
Loncar Investments

Dr Kuldeep Neote

Senior Director of New Ventures
Johnson & Johnson

Dr Ramy Ibrahim

VP Clinical Development
The Parker Institute

Timothy Fisher

Global Lead, Search & Evaluation, Oncology
Bristol Myers Squibb

Alessandra Polara

BD&L Director
Roche Partnering

Dr Timothy Herpin

Vice President, Head of Transactions, Business Development
AstraZeneca

Ferran Prat

Senior Vice President, Research Administration & Industry Relations
MD Anderson Cancer Center

Dr Mark Throsby

CSO
Merus

Dr Bent Jakobsen

CSO
Immunocore

Dr Laszlo Radvanyi

SVP Head of ImmunoOncology Translational Innovation Platform
EMD Serono

Dr William Grossman

Global Development Team Leader Tecentriq - GI & Cancer Immunotherapy Combinations -Solid Tumors
Genentech

Dr Keith Knutson

Director, Cancer Vaccine & Immune Therapies Program
Mayo Clinic

Dr. James J. Mulé

Associate Center Director, Translational Research, Director of Cell-Based Immunotherapies
Moffitt Cancer Center

Dr John Beadle

CEO
PsiOxus

Dr Pawel Kalinski

Vice Chair for Translational Research and Professor of Oncology, Department of Medicine, Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Co-Leader, Tumor Immunology & Immunotherapy Program
Roswell Park Cancer Institute

Dr Stephen Doberstein

SVP & CSO
Nektar Therapeutics

Dr Vamil K Divan

Senior Research Analyst
Credit Suisse LLC

Dr Jeffrey Miller

Deputy Director of the Masonic Cancer Center
University of Minnesota

Professor Eric Ahrens

Professor of Radiology
University of California San Diego

Dr Peter Ordentlich

CSO & Founder
Syndax Pharmaceuticals

Dr Martin Oft

Founder & Vice President of Pre-Clinical & Clinical Development
Armo Biosciences

Dr Masahide Yano

Research Scientist, Center for Drug Evaluation & Research
FDA (Provisionally Confirmed)

Dr. Francesco Galimi

Global Product General Manager, Early Development
Amgen, Inc.

Dr Christopher Heery

Chief Medical Officer
Bavarian Nordic

Dr Evren Alici

CEO, **Vycellix**; Director Cell & Gene Therapy Centre
Karolinska Institute

Dr Asthika Goonewardene

Senior Biotech Analyst
Bloomberg Industries

Dr William Logging

Head, Production Bioinformatics, Genetics & Genomics Sciences, **Icahn School of Medicine Mount Sinai**

Dr Patrick Tricoli

CEO
Nanobiotix US

Dr Stephen Cary

CEO
Omniox

Shawn Iadonato, PhD.,

CEO
Kineta Immuno-Oncology

Dr Joanne Bedwell-Garner

Development Director
Macrophage Pharma

Dr Frank Tufaro

CEO
DNatrix Therapeutics

Dr Ravi Madan

Clinical Director Genitourinary Malignancies
National Cancer Institute

Scott Bornheimer PhD


Applied Research Manager
BD Biosciences

Mark Gardner

CEO
OmniSeq, Inc


EXPERIENCE THE WORLD IMMUNO-ONCO

SECOND FLOOR



 STAIRS
 CATERING

'S LARGEST SHOWCASE OF BIOLOGY PIONEERS





IO COLLABORATION LUNCH

Meet more Big Pharma decision makers in 45 minutes than you would all year whilst enjoying the sunshine on the river walk terrace. We are giving you access to the influencers from big pharma making this THE optimal networking opportunity for biotechs/academic centres on the hunt for clinical partnerships.

TRANSLATION ACADEMY

Phacilitate and Bio Insights have teamed up to further support collaboration between academic and industry pioneers. The Translation Academy will highlight promising innovation and support its path to commercial success.

PHACILITATE'S IMMUNO-ONCOLOGY HUB

Will give senior leaders from biotech and pharma the chance to gain expert insight from technology enablers just when they're actively seeking partners to progress their programs



PHACILITATE TRAINING

Having an adequately skilled workforce has been identified as a major speed-bump to industrialisation, and as we see more practitioners join from adjacent sectors, you told us it was important to learn new and important skills.

Call us on +44 207 384 7993 to find out more about our CPD accredited training day!

TOP INDUSTRY SPEAKERS INCLUDE



JAPANESE PARTNERING LUNCH

This dedicated networking session delivers a unique opportunity to enable new partnerships and discussions with attendees from Japan

YACHT PARTY

Our legendary yacht party returns bigger and better than before for 2018! Tickets are limited and will be allocated on a first come, first served basis so don't miss out!



CO-LOCATION WITH CELL & GENE THERAPY WORLD

The only I-O event co-located with the leading Cell and Gene Therapy global meeting. Providing access to the most commercially advanced technical expertise specifically for cellular immunotherapies. As a combined event we will have 1,200+ attendees, 200+ speakers, 100+ exhibitors – it is the one meeting on the global calendar attended by all of the critical decision-makers from both inside and outside of the cell & gene therapy/ immuno-oncology industry.



AGENDA AT-A-GLANCE

PRE-CONFERENCE DAY - MONDAY, JANUARY 22

Facilitate Training

4 bespoke, half-day, CPD accredited training courses with sector-leading experts, giving you a vital edge in either partnering strategy or product development/manufacturing Cell & Gene Therapy Product Characterization // Quality by Design Pharma Partnering Bootcamp // Partnering in Japan

16.30: Main Registration Opens

18.00-19.30: Super Plenary

19.30: Welcome Reception

DAY 1 - TUESDAY, JANUARY 22

Plenary: Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

Stream 1- I-O strategy

Responders vs non-responders

Rational Combination therapy

Precision medicine

Stream 2- Emerging Science

Immune Suppressive Pathways

Cellular immunotherapy beyond CD19

Bispecific antibodies

DAY 2 - WEDNESDAY, JANUARY 24

Plenary: The science of investment & collaboration: winning the immuno-oncology business battle

Stream 1- I-O strategy

Translational Tools and Technologies

Hot vs warm vs cold tumors

Stream 2- Emerging Science

Cancer vaccine approaches

Combinations in the clinic

Immuno-hub showcases

DAY 3 - THURSDAY JANUARY 25TH

Deep-Dive workshops

SPONSORS

Platinum sponsors

ThermoFisher
SCIENTIFIC

Gold Sponsors



Silver Sponsors



Bronze Sponsors



HOW TO REGISTER

Head to www.iofrontiersworld.com to register now for our super early bird rates, saving you \$\$\$'s!

SUPER EARLY BIRD

Ends Friday 20th Oct

Delegate Type	Rates
Pharma/Biotech	\$2,595
Technology/Service Provider	\$3,995
Academic/Government/Not-for-Profit	\$1,195

EARLY BIRD

Ends Friday 1st Dec

Delegate Type	Rates
Pharma/Biotech	\$2,695
Technology/Service Provider	\$3,995
Academic/Government/Not-for-Profit	\$1,395

FULL RATE

Delegate Type	Rates
Pharma/Biotech	\$2,895
Technology/Service Provider	\$3,995
Academic/Government/Not-for-Profit	\$1,595

FOR INFORMATION ON:

Small company rates • Group discounts • 1-day attendance rate
Please email team@phacilitate.co.uk or call +44 (0)20 7384 7993